11-9-10 Daily Small Cap Market News and Stock Highlights from SmallCapVoice.com

David K. Randall, Associated Press Business Writer

Stocks mixed in early trading; Gold jumps

Stocks mixed in early trading, European shares rebound, gold up

NEW YORK (AP) — Stocks are narrowly mixed in early trading, one day after the stock market's most watched measure snapped a six-day streak of gains.

Gold is extending its gains Tuesday after closing at a record high on Monday. The precious metal is now trading at $1,420 an ounce. Investors have been buying gold on fears of inflation and a weaker dollar. Global stocks are mixed.

In corporate news, Chevron announced it will buy natural gas producer Atlas Energy for $3.2 billion.

The Dow Jones industrial average is down 22, or 0.2 percent, to 11,385. The S&P 500 is down 1, or 0.1 percent, to 1,223, while the Nasdaq composite index is up 1, or 0.1 percent, to 2,581.

Yesterday's Top Performing Small Cap Stock:

Tootie Pie Company TOOT

Tootie Pie Company was a SmallCapVoice.com top performer closing up over 4% on trading volume of 17,663 shares.

Tootie Pie Company bakes and sells high-quality, handmade pies through three basic sales channels: retail, corporate and wholesale. The retail segment serves individual consumers through in-store sales, orders via telephone and internet on the Company's website. The corporate segment serves businesses that purchase pies as a way to promote their company through client and employee appreciation programs. The wholesale segment is made up of national and regional broad line grocery and foodservice distributors who purchase pies and then resell them through their respective sales distribution channels.

Today's SmallCapVoice.com Hot Stock to Watch:

BRAVADA International Ltd (Pink Sheets: MFLI)

BRAVADA International is a company specializing in womens, health, fitness and lifestyle apparel products and owns and operates BRAVADA Women's Athletica, an exclusively women's fitness apparel retail store as well as BravadaWomen.com.

BRAVADA Women's Athletica is a womens only retail store specializing in health, fitness and lifestyle apparel and with the very best in women's fashion activewear, fitness as well as yoga clothes. BRAVADA has been compared to a young Lululemon however, BRAVADA is much more. BRAVADA is all about getting excited about being a woman with sassy sexy styling as well as basic solids and inspiring designs for any mood and activity. BRAVADA's women's athletic apparel is designed to inspire a woman before, after & during her workout.

BravadaWomen.com is the online ecommerce retail site for BRAVADA Women's Athletica. With hundreds of styles, colors and designs as well as sensible and practical in-home fitness equipment, BravadaWomen.com provides the very best in women's fashion activewear.

Other Small Cap News

IsoRay, Inc. (NYSE Amex: ISR)

IsoRay Awarded More Than $526,000 in Federal Grants for Breast, Brain and Lung Cancer

Funding to Advance Adoption of Cesium-131 Internal Radiation Therapy Throughout the Body

RICHLAND, Wash.–(BUSINESS WIRE)– IsoRay, Inc. ISR announced, today, it has been awarded $526,910 under the IRS Qualifying Therapeutic Discovery Program (QTDP). Created by Congress, the program is part of the Patient Protection and Affordable Care Act of 2010. The QTDP provides financial support for innovative projects that the U.S. Department of Health and Human Services believes could well result in a new therapy, reduce health care costs, or represent an important advance in finding a cure for cancer.

YM BioSciences Inc. (NYSE Amex: YMI)

Ym Biosciences Reports Significant Response Rates in Anemia, Splenomegaly, and Constitutional Symptoms From the Phase I/II Trial of its Jak1/Jak2 Inhibitor, Cyt387, in Myelofibrosis

Results to be presented at the 52nd American Society of Hematology Annual Meeting

MISSISSAUGA, ON, Nov. 8 /PRNewswire-FirstCall/ – YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced that data from the initial portion of the Phase I/II trial of its JAK1/JAK2 Inhibitor, CYT387, will be reported in an oral presentation at the 52nd American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida on December 4-7th, 2010. The presentation is entitled: “A Phase I/II Study of CYT387, an oral JAK-1/2 inhibitor, in Myelofibrosis: Significant Response Rates in Anemia, Splenomegaly, and Constitutional Symptoms”. The abstract describing these results was published online today by ASH and is also available at YM BioSciences' website (www.ymbiosciences.com).

Jingwei International Limited JNGW

Jingwei International Limited Enters Into Definitive Agreement to Acquire Shanghai Haicom Limited and Raises FY 2010 Net Income Guidance

SHENZHEN, China, Nov. 8, 2010 /PRNewswire-Asia-FirstCall/ — Jingwei International Limited JNGW (“Jingwei” or “the Company”), a leading provider of data-mining, interactive marketing and software services in China, today announced that it has entered into a definitive agreement to acquire Shanghai Haicom Limited (“Haicom”), a Shanghai-based Internet and mobile value added service platform provider with business operations covering ten provinces in the People's Republic of China. Terms of the definitive agreement are consistent with the previously announced framework agreement and stipulate that Jingwei will acquire 100% of Haicom in exchange for RMB 35 million, or approximately $5.2 million, in cash and up to 667,802 shares of stock, depending on compliance with revenue and earnings targets for the fiscal year ending December 31, 2011

Prana Biotechnology PRAN

Prana Biotechnology Plans to Advance Alzheimer's Clinical Trial

Re-Elected Victorian Labor Government Pledges $15 Million AUD Towards the Trial

NEW YORK, NY–(Marketwire – 11/08/10) – Prana Biotechnology PRAN PBT has today announced it has received confirmation that a re-elected Victorian Labor Government would commit $15 million AUD to the Mental Health Research Institute (MHRI) as crucial funding toward the commencement of a large scale trial of PBT2. MHRI is Prana Biotechnology's long standing partner in Alzheimer's research and PBT2 is its lead compound for the treatment of Alzheimer's and Huntington's Disease.

CECO Environmental Corp. CECE

CECO Environmental Announces New $2.5 Million Order

CINCINNATI, Nov. 9, 2010 /PRNewswire/ — CECO Environmental Corp. CECE, a leading provider of air pollution control and industrial ventilation systems, announced today that it has received a new order for $2.5 million from a global refining customer.

Jeff Lang, CECO's Chief Executive Officer, commented, “I am very excited with this significant order. CECO has experienced increasing demand across all of our divisions from our global customer base.”

Array BioPharma Inc. ARRY

Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2011

BOULDER, Colo.–(BUSINESS WIRE)– Array BioPharma Inc. ARRY today reported financial results for the first quarter of fiscal 2011.

Array reported revenue of $18.5 million for the first quarter of fiscal 2011, compared to revenue of $7.9 million for the same period in fiscal 2010. Array spent $13.9 million in proprietary research and development for the quarter to advance its clinical development and discovery programs. This compares to $19.2 million spent on proprietary research and development during the first quarter of fiscal 2010. Array reported a net loss of $10.6 million, or ($0.20) per share, for the first quarter, compared to a net loss of $24.8 million, or ($0.52) per share, for the first quarter in fiscal 2010. Array ended the first quarter of fiscal 2011 with $109 million in cash, cash equivalents and marketable securities.

Pharmacyclics, Inc. PCYC

Pharmacyclics Reports Recent Developments and Financial Results for Fiscal First Quarter 2011

Total revenue was $2.0 million for the fiscal quarter ended September 30, 2010. Upon the signing of a drug supply agreement with Les Laboratoires Servier (“Servier”) in the quarter ended December 31, 2009, the company began recognizing revenue from its collaboration agreement with Servier, which was entered into in April 2009. No revenue was generated in the fiscal quarter ended September 30, 2009.

As of September 30, 2010, the company had cash, cash equivalents and marketable securities totaling $67.8 million. This compares with $74.1 million in cash, cash equivalents and marketable securities as of June 30, 2010. We received the third scheduled payment of $1.0 million from our Collaboration and License Agreement with Les Laboratoires Servier in November 2010 and we expect to receive the fourth and final payment of $1 million in the second calendar quarter of 2011.

About SmallCapVoice.com

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide. Known for its ability to help emerging growth companies build a following among retail and institutional investors, SmallCapVoice.com utilizes its stock newsletter to feature its audio interviews, as well small cap company's financial news releases. SmallCapVoice.com also offers individual investors with all the tools they need to make informed decisions about the stocks they are interested in. Tools like our stock charts, stock alerts, and our company information sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets.

The SmallCapVoice.com, Inc. Daily Highlights is an electronic publication, and is for informational purposes only. The Small Cap Voice Daily Highlights covers both client and non client issuers. Non client issuer's news is listed under other small cap news. SmallCapVoice is an electronic publication providing information on selected public companies. All companies profiled on this website pay cash or restricted stock to SmallCapVoice as consideration for the electronic dissemination of the company's information and our comments about the company. Section 17(b) of the Securities Act of 1933 requires that SmallCapVoice fully disclose the type consideration (i.e. cash, restricted stock, and restricted stock with registration rights, stock options, stock warrants, or other type consideration) and the specific amount of the consideration our company receives or will receive, directly or indirectly, from an issuer, underwriter, or dealer. No information contained in our website, e-mail communications or our publications should be considered as a solicitation to purchase or sell the securities of the profiled companies. SmallCapVoice is not a registered investment advisor or a registered securities broker dealer. We do not undertake or represent to make investment recommendations or to give advice pertaining to the purchase or sale of the securities mentioned in our web site, e-mail communications or publications. The information contained in our website, e-mail communications and publications are carefully compiled by SmallCapVoice from public sources that we believe to be reliable. SmallCapVoice, however, does not guarantee the accuracy of any information contained in our website, e-mail communications or publications. This material is not a substitute for either one's own thorough investigation of an investment opportunity or the exercise of good business judgment. SmallCapVoice does not endorse, independently verify, or assert the truthfulness or reliability of any statements or data obtained from third party sources that are published by us about the profiled companies in our website articles, e-mail communications or publications, but we do not publish information that we know is incorrect. Investors should not rely solely on the information contained in our website, e-mail communications or publications when making investment decisions. Instead, investors should use the information provided on the profiled companies as a starting point for conducting additional research that will permit them to form their own opinions regarding the appropriateness of an investment in the profiled company's securities. SmallCapVoice does not warrant, represent or guaranty that there has been no change in the affairs of the profiled company since the date that information was published on this website, in e-mail communications or in our publications regarding a profiled company or after the date of the profiled company's press releases or other information disseminated via our website or publications. If you become aware of any change of circumstances related to any website article, e-mail communication or publication, please notify us immediately. See the Contact Us page for the appropriate e-mail address. The information contained in our website, e-mail communications and publications pertains to microcap, small cap and/or other thinly traded securities which by their very nature involve an extremely high degree of risk. An investment in these type of securities could result in the loss of some or all of an investment in the company. In addition, due to the illiquid nature of some of these securities, an investor may find encounter difficulties in liquidating the securities. SmallCapVoice may liquidate the stock consideration it receives at any time it deems it appropriate to do so after the required six-month holding period has run after the completion of the services for which SmallCapVoice was paid in stock. The liquidation of our stock may have a negative impact on the securities of the company liquidated, including decreased market value and/or dilution of the company's securities. The following companies have paid, and/or have agreed to pay SmallCapVoice to: distribute the company's information and reports on this website, to send e-mail communications; to send publications by mail, to post company Internet links on our website, and to compile and/or to distribute reports in an e-mail newsletter.

We encourage our readers to use caution when investing and educate themselves at the web sites of the Securities and Exchange Commission (“SEC”) at www.sec.gov and/or the National Association of Securities Dealers (“NASD”) at www.nasd.com. We encourage you to study the SEC's policies regarding online newsletters at http://www.sec.gov/answers/newsltr.htm. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our site.

Contact:

Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
http://www.smallcapvoice.com